Skip to content Skip to sidebar Skip to footer

Newsletter

Biotech Stocks

Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product

Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in Australia, New Zealand and Singapore, plus approval is pending in Canada and Thailand. But the US was the biggest piece of the US$3.5bn pie that is the company's global addressable market, and now it is…

ByNick SundichApril 4, 2025

Should you use your tax cut to invest in stocks? And how should you go about it?

Should you use your tax cut to invest in stocks? With another unexpected round of tax cuts starting from the middle of next year, unveiled in the federal budget earlier this week, this is a question facing many. This round isn't that large - only $536 a year and little over $10 a week by…

ByNick SundichMarch 27, 2025

Truscreen (ASX:TRU): Taking a radical path to wide-spread commercialisation

Truscreen (ASX:TRU) is not taking the conventional path ASX medtech stocks take to market. Typically they seek approval in the US and then use that to set up shop across the world. Truscreen is instead starting its journey in Low-to-Middle Income Countries (LMICs). And even though shareholders may not realise it, this may actually be…

ByNick SundichMarch 12, 2025

Atomo Diagnostics (ASX:AT1): Not just another Rapid Diagnostic (RDT) company

Atomo Diagnostics (ASX:AT1) may be written off by some investors just because it is a rapid test kit company. Yes, we know rapid COVID tests were a booming market during the pandemic, but demand is well off all time highs - and indeed, the company no longer performs COVID testing. But there was, is and…

ByNick SundichFebruary 26, 2025

Nanosonics (ASX:NAN): A disinfection company turning itself around and has gained 50% so far in 2025

Nanosonics (ASX:NAN) was in the best space to be during the pandemic - disinfection technology. Its flagship Trophon machines are electron paramagnetic resonance (EPR) devices aimed to reduce cross contamination in hospitals and other healthcare settings, particularly through ultrasound probes which have conventionally been hand-wiped. Source: Company The company has over 30,000 of these deployed worldwide and…

ByNick SundichFebruary 25, 2025

Will the RBA cut rates in February? 3 reasons why they might and 3 reasons why they might not!

Will the RBA cut rates in February? That's the question on everyone's minds. The board will hold its first meeting for the year on February 17-18 and everyone wants to know if a rate cut will happen. Only time will tell. There are also some important metrics to be released in the next month including…

ByNick SundichJanuary 16, 2025

Here are our 6 Best ASX Stocks for 2025 and why you should give them a look!

Here are our 6 Best ASX Stocks for 2025! Opthea (ASX:OPT) Its been a long wait, but 2025 will finally be the year Opthea (ASX:OPT) investors receive Phase 3 results. Opthea is an optometry biotech developing Sozinibercept - a drug fighting wet AMD. Wet AMD is the leading cause of blindness, impacting 3.5m people annually…

ByNick SundichDecember 27, 2024

5 Promising Stocks Fighting Alzheimers to Watch Now

Let's take a look at the most promising stocks fighting Alzheimers disease. Alzheimer’s disease is one of the most daunting medical challenges of our time, with millions affected worldwide and no definitive cure in sight. There are few drugs that can fight Alzheimer’s, and they only fight symptoms and may not work until a later…

ByUjjwal MaheshwariDecember 19, 2024

the Kick-ass Multipurpose WordPress Theme

Biotech Stocks

Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product

Should you use your tax cut to invest in stocks? And how should you go about it?

Truscreen (ASX:TRU): Taking a radical path to wide-spread commercialisation

Atomo Diagnostics (ASX:AT1): Not just another Rapid Diagnostic (RDT) company

Nanosonics (ASX:NAN): A disinfection company turning itself around and has gained 50% so far in 2025

Will the RBA cut rates in February? 3 reasons why they might and 3 reasons why they might not!

Here are our 6 Best ASX Stocks for 2025 and why you should give them a look!

5 Promising Stocks Fighting Alzheimers to Watch Now

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Biotech Stocks

Add Your Heading Text Here